Cancer researchers test speeding up Life-Saving drug dosing
NCT ID NCT04843904
Summary
This study is testing a faster, daily schedule for increasing the dose of the drug venetoclax in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this accelerated 5-day schedule is as safe as the standard 5-week schedule, especially for patients with different risks of a side effect called tumor lysis syndrome. About 40 adults with newly diagnosed or returning CLL/SLL will participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.